Literature DB >> 14508188

Blood pressure is insufficiently controlled in European patients with established coronary heart disease.

Eric Boersma1, Ulrich Keil, Dirk De Bacquer, Guy De Backer, Kalevi Pyörälä, Don Poldermans, Cristiana Leprotti, Lorenza Pilotto, Esther de Swart, Jaap W Deckers, Jan Heidrich, Susana Sans, Kornelia Kotseva, David Wood, Giovanni B Ambrosio.   

Abstract

BACKGROUND: Elevated blood pressure is associated with an impaired prognosis in patients with established coronary heart disease. Adequate blood pressure control is therefore of utmost importance. We report on two successive European surveys that evaluated whether the goals given in recommendations on secondary prevention are achieved.
METHODS: The first European Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE I) survey was conducted during 1995-1996 in 21 hospitals in nine European countries. The second survey (EUROASPIRE II) was conducted during 1999-2000 in 47 hospitals (including 20 hospitals that participated in EUROASPIRE I) in 15 Europeans countries. Consecutive patients (aged < 71 years) were identified from hospital records after coronary artery bypass grafting, percutaneous coronary intervention, myocardial infarction, or myocardial ischaemia. Patients were invited for an interview and examination at least 6 months after hospitalization. During the interview, blood pressure was measured in a standardized fashion. Systolic blood pressure >/= 140 mmHg and/or a diastolic blood pressure >/= 90 mmHg were considered as elevated blood pressure. EUROASPIRE II provides a more comprehensive view on the actual management of patients with established coronary disease. Therefore, we decided to concentrate mainly on the EUROASPIRE II data, and to use EUROASPIRE I for the evaluation of time trends.
RESULTS: In EUROASPIRE II, 5556 patients were interviewed, and 51% were diagnosed with elevated blood pressure. Large regional variations in the prevalence of elevated blood pressure were observed, with values ranging from 37 to 64%. Twenty-five per cent (1401) of patients were on a diet to reduce blood pressure, and among these 61% had elevated blood pressure. The prevalence of elevated blood pressure among the 4827 (87%) patients taking blood pressure-lowering medication (which was not necessarily taken as an antihypertensive treatment) was 51%. Patients with elevated blood pressure were more likely to be diabetic, hypercholesterolemic, and obese than normotensive patients. The proportion of patients who reported being aware of their hypertensive status was somewhat higher in EUROASPIRE II than in EUROASPIRE I (71 versus 67%), and the use of blood pressure-lowering medication was intensified (91 versus 85%). However, these changes were not accompanied by a decrease in the prevalence of elevated blood pressure (54 versus 55% in centres that participated in both surveys).
CONCLUSION: During 1995-2000 the prevalence of elevated blood pressure in patients with established coronary heart disease remained at an unacceptably high level. Throughout Europe, still about half of coronary patients require more intensive blood pressure management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508188     DOI: 10.1097/00004872-200310000-00009

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

1.  The changing role of hypertension societies: shifting gears in Italy.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-03-01

2.  Changes in the usage of antihypertensive drugs: implications and prospects.

Authors:  Mike Schachter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

3.  2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

4.  [Lupus in Germany: analysis within the German lupus self-help organization (LULA)].

Authors:  R Fischer-Betz; E Wessel; J Richter; B Winkler-Rohlfing; R Willers; M Schneider
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 5.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

6.  The ROVIGO study (risk of vascular complications: impact of genetics in old people): protocol, study design, and preliminary results of the initial survey : cardiovascular epidemiology in the elderly.

Authors:  Alberto Mazza; Sergio Zamboni; Emilio Ramazzina; Laura Schiavon; Panagiota Rempelou; Sara Zorzan; Anna Bascelli; Rosa Segato; Rossana Redi; Elisa Pagnin; Alessandro Camerotto; Marco Zuin; Enzo Rizzato; Adriano Marcolongo; Arturo Orsini; Domenico Rubello; Edoardo Casiglia
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-10-23

7.  Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting.

Authors:  Sanna-Maria Michou; Mika Kähönen; Terho Lehtimäki; Kjell Nikus; Jari Viik; Kari Niemelä; Janne Kallio; Rami Lehtinen; Tiit Kööbi; Väinö Turjanmaa; Tuomo Nieminen
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Cardiovascular risk in hypertension - can we ask for more? : focus on aliskiren.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

9.  How do family physicians communicate about cardiovascular risk? Frequencies and determinants of different communication formats.

Authors:  Stefan Neuner-Jehle; Oliver Senn; Odette Wegwarth; Thomas Rosemann; Johann Steurer
Journal:  BMC Fam Pract       Date:  2011-04-05       Impact factor: 2.497

10.  Sex differences in the hypertensive population with chronic ischemic heart disease.

Authors:  Vivencio Barrios; Carlos Escobar; Vicente Bertomeu; Nekane Murga; Carmen de Pablo; Alberto Calderón
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.